🇺🇸 FDA
Patent

US 11571444

Enhancement of MSC immunomodulatory properties by treprostinil

granted A61KA61K31/192A61K35/28

Quick answer

US patent 11571444 (Enhancement of MSC immunomodulatory properties by treprostinil) held by United Therapeutics Corporation expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/192, A61K35/28, A61P, A61P11/00